TLDR Simvastatin/ezetimibe may help treat new cases of alopecia areata but not long-term cases.
The document discussed the potential of simvastatin/ezetimibe as a treatment for alopecia areata (AA), an autoimmune disorder marked by T lymphocytic infiltrates around hair follicles. Statins were considered promising due to their modulation of the JAK/STAT pathway. Evidence suggested that statins might be effective for acute AA but not for chronic, longstanding cases. Animal studies indicated that statin treatment increased CD4+/CD25+/Foxp3+ populations in AA-affected mice.
14 citations
,
January 2017 in “Skin appendage disorders” Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
391 citations
,
January 2010 in “Journal of The American Academy of Dermatology” Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.
April 2019 in “Journal of Investigative Dermatology” Simvastatin reduces inflammation and promotes hair regrowth in alopecia areata.
2 citations
,
March 2015 in “Expert opinion on orphan drugs” New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
16 citations
,
June 2017 in “Advances in Therapy” New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.
13 citations
,
January 2017 in “Annals of dermatology/Annals of Dermatology” Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.
82 citations
,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
